We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Inovio Biomedical to Present DNA Delivery Technology at Drug Delevery Conference

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Inovio Biomedical to Present DNA Delivery Technology at Drug Delevery Conference"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Inovio Biomedical Corp. has announced that its Executive Director of Corporate Development, Dr. Michael Fons, will present new developments in Inovio’s DNA immunotherapy programs at the Arrowhead Drug Delivery 2007 conference to be held April 9 to 11 at the Crowne Plaza Union Square in San Francisco, CA.

Dr. Fons’ presentation will cover key aspects of non-viral DNA delivery via electroporation of four different partnered immunotherapy products that are currently in clinical evaluation for cancers including prostate, breast, ovarian, colorectal, melanoma and small cell lung cancer.

The presentation will reference pre-clinical studies demonstrating safety and efficacy in animal models of cancer and infectious diseases and highlights of the regulatory approach used to permit clinical evaluation of these novel drug-device combination therapeutic products.

"Our DNA-based immunotherapy programs have gained enormous momentum over the past year," stated Avtar Dhillon, MD, president and CEO of Inovio.

"We believe we are on the verge of obtaining clinical data to validate the tremendous potential previously demonstrated in animal models of DNA-based immunotherapies delivered using Inovio’s DNA delivery solution. We look forward to a number of exciting developments in immunotherapy development programs using our proprietary electroporation technology over the coming years," said Dhillon.